A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms KEYNOTE-017
- Sponsors Merck & Co
- 17 Oct 2019 Status changed from completed to active, no longer recruiting.
- 12 Sep 2019 Status changed from active, no longer recruiting to completed.
- 06 Feb 2019 Long term follow up results of this trial, were published in the Journal of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History